MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Abbott Laboratories

Chiusa

SettoreSettore sanitario

128.47 1.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

128.47

Massimo

129.22

Metriche Chiave

By Trading Economics

Entrata

454M

1.8B

Vendite

784M

11B

P/E

Media del settore

16.484

36.442

EPS

1.26

Rendimento da dividendi

1.75

Margine di Profitto

15.967

Dipendenti

114,000

EBITDA

383M

3B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+14.07% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.75%

3.00%

Prossima data del Dividendo

17 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1B

229B

Apertura precedente

127.46

Chiusura precedente

128.47

Notizie sul Sentiment di mercato

By Acuity

57%

43%

296 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Abbott Laboratories Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 ott 2025, 12:02 UTC

Utili

Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

17 lug 2025, 12:10 UTC

Utili

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

15 ott 2025, 16:15 UTC

Utili

Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. -- Barrons.com

15 ott 2025, 12:25 UTC

Utili

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. -- Barrons.com

15 ott 2025, 11:32 UTC

Utili

Abbott Labs Still Sees 2025 Organic Sales Up 6%-7% Including Covid-19 Testing-Related Sales >ABT

15 ott 2025, 11:32 UTC

Utili

Abbott Labs Still Sees 2025 Organic Sales Up 7.5%-8% Excluding Covid-19 Testing-Related Sales >ABT

15 ott 2025, 11:31 UTC

Utili

Abbott Labs Sees 2025 Adj EPS $5.12-Adj EPS $5.18 >ABT

15 ott 2025, 11:30 UTC

Utili

Abbott Labs 3Q Adjusted Operating Margin 23% >ABT

15 ott 2025, 11:30 UTC

Utili

Abbott Labs Reaffirms Full-Year Guidance >ABT

15 ott 2025, 11:30 UTC

Utili

Abbott Labs 3Q Organic Sales Growth Up 5.5% >ABT

15 ott 2025, 11:30 UTC

Utili

Abbott Labs 3Q Sales $11.37B >ABT

15 ott 2025, 11:30 UTC

Utili

Abbott Labs 3Q Adj EPS $1.30 >ABT

15 ott 2025, 11:30 UTC

Utili

Abbott Labs 3Q Net $1.64B >ABT

15 ott 2025, 11:30 UTC

Utili

Abbott Labs 3Q EPS 94c >ABT

11 ott 2025, 00:18 UTC

Acquisizioni, Fusioni, Takeovers

Why Biotech May Be Back -- Barrons.com

17 lug 2025, 13:14 UTC

Utili

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 lug 2025, 12:16 UTC

Utili

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 lug 2025, 11:32 UTC

Utili

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 lug 2025, 11:32 UTC

Utili

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 lug 2025, 11:31 UTC

Utili

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Sales $11.14B >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Net $1.78B >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 lug 2025, 11:30 UTC

Utili

Abbott Labs 2Q EPS $1.01 >ABT

17 lug 2025, 09:08 UTC

Azioni calde

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

Confronto tra pari

Modifica del prezzo

Abbott Laboratories Previsione

Obiettivo di Prezzo

By TipRanks

14.07% in crescita

Previsioni per 12 mesi

Media 146.63 USD  14.07%

Alto 162 USD

Basso 136 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Abbott Laboratories - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

18

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

132.82 / 134.43Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

296 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat